![Healthcare reality of the treatment of the high-risk multiple myeloma in Spain | Medicina Clínica (English Edition) Healthcare reality of the treatment of the high-risk multiple myeloma in Spain | Medicina Clínica (English Edition)](https://multimedia.elsevier.es/PublicationsMultimediaV1/file//23870206/0000015400000008/v1_202004190641/S2387020620301029/v1_202004190641/en/main.assets/gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w997EogCnBdOOD93cPFbanNeMnx59J5MZq19QkIYapO3CcJ9CENpsFcm3MeAXF+MMxsJrl5MogwoNyiiPrWn5EolbGSaePAm7SObORQuBLnHrM7CHCTbkUMrraqmu9cvf1qcxz0uTdfKiScYAzZBdozn4RNxKvbrW1xfvj96Wx8aFuv5gLgcpBQnzBEHunHoxsilEuXZRoaDm7WdrsaQBmiuGI5lCZ4jflFZAD2nf1t0QJnzMMzv4L/Ix2pS6xV59L8TLJrVsDqnNYVGfxcAnMgk=)
Healthcare reality of the treatment of the high-risk multiple myeloma in Spain | Medicina Clínica (English Edition)
Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma
![Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/4054c0bb-6add-4d79-a311-e460cd3357f2/gr1.gif)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
![Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS) | Annals of Hematology Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS) | Annals of Hematology](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00277-021-04522-y/MediaObjects/277_2021_4522_Fig3_HTML.png)
Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS) | Annals of Hematology
![Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse](https://pub.mdpi-res.com/curroncol/curroncol-30-00179/article_deploy/html/images/curroncol-30-00179-g001.png?1676859747)
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
![Biomedicines | Free Full-Text | Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting Biomedicines | Free Full-Text | Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting](https://pub.mdpi-res.com/biomedicines/biomedicines-11-02087/article_deploy/html/images/biomedicines-11-02087-g002.png?1690358657)
Biomedicines | Free Full-Text | Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
![Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena](https://www.drugdevelopment-technology.com/wp-content/uploads/image-digitalinsightresearch/Archive/nri/Drug%20development/Multiple%20myeloma.jpg)
Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena
![Patient characteristics of 130 relapse and refractory multiple myeloma... | Download Scientific Diagram Patient characteristics of 130 relapse and refractory multiple myeloma... | Download Scientific Diagram](https://www.researchgate.net/publication/333885272/figure/tbl1/AS:771702611001344@1560999648124/Patient-characteristics-of-130-relapse-and-refractory-multiple-myeloma-RRMM-candidates.png)
Patient characteristics of 130 relapse and refractory multiple myeloma... | Download Scientific Diagram
![Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews - ScienceDirect Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1040842822002669-ga1.jpg)
Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews - ScienceDirect
![Cells | Free Full-Text | Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications Cells | Free Full-Text | Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications](https://www.mdpi.com/cells/cells-10-00336/article_deploy/html/images/cells-10-00336-g001.png)